| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
2026 has been one of the hardest years for Indian equity investors in over a decade. The Nifty 50 total return index (TRI) is down 10.9% from 1 January to 30 October, and the Sensex is down 12.6%.
Foreign investors (FIIs) have pulled about Rs 2.5 lakh crore out of Indian shares in the first nine months, and the Sensex and Nifty recorded their weakest nine-month run since 2011.
Against that, 394 of the 547 actively managed equity funds have lost money, and the median fund has lost 4.6%.
But there are some standouts as well which have delivered up to 78% returns in 2026 so far.
Let's look at the top 5 in more detail.
Please note, we have considered all 1,097 equity schemes and their year-to-date return from 1 January to 30 October 2026 (NAVs of 30 or 31 October).
We have also removed index funds and ETFs, which are passive, leaving 547 active schemes with a 2026 return, and ranked them by that return.
The table below shows how unusual the top is. Every global fund and every pharma and healthcare fund in the data was positive, and small caps were mostly positive, while large caps, tax-saving funds and value funds almost all lost money.
Only one of 33 large cap funds and two of 40 tax-saving (ELSS) funds are in the green in 2026 so far.
| Category | Funds | Positive | Median return | Best fund | Best return |
|---|---|---|---|---|---|
| Global | 6 | 6 | 17.80% | Nippon India Taiwan Equity Fund | 78.20% |
| Pharma and healthcare | 18 | 18 | 15.20% | Kotak Healthcare Fund | 25.60% |
| Small cap | 33 | 26 | 5.70% | Bank of India Small Cap Fund | 21.30% |
| Focused | 28 | 6 | -5.00% | Motilal Oswal Focused Fund | 18.20% |
| Value | 22 | 2 | -8.00% | LIC MF Value Fund | 10.20% |
| Multi cap | 32 | 12 | -1.10% | Motilal Oswal Multi Cap Fund | 9.30% |
| Mid cap | 31 | 10 | -2.60% | HSBC Midcap Fund | 8.90% |
| Large and mid cap | 33 | 4 | -4.60% | Quant Large and Mid Cap Fund | 5.00% |
| ELSS (tax saving) | 40 | 2 | -6.70% | Motilal Oswal ELSS Tax Saver Fund | 4.60% |
| Flexi cap | 44 | 11 | -3.90% | ITI Flexi Cap Fund | 4.10% |
| Large cap | 33 | 1 | -7.90% | Taurus Large Cap Fund | 2.80% |
Two reasons stand out. Small and midsize companies held up better than large ones because foreign investors, who own mainly large caps, were the main source of exits, while domestic investors kept adding through SIPs.
And pharma held up because exporters earn in dollars, and the rupee touched a record low of 96.38 a dollar in May. Healthcare is also seen as a defensive sector when markets are volatile, and the Nifty Pharma TRI returned 20.1% in the period.
With that out of the way, let's move on to individual funds.
The table topper is Nippon's Taiwan Equity fund. It has returned 78.2%, nearly three times the next best fund of all.
Its benchmark, the TAIEX, gained 56.1% in Taiwan dollars as artificial intelligence hardware drove Taiwanese shares to repeated record highs.
The fund's return is in rupees and the index's is in Taiwan dollars, so the 22-point gap cannot be split between stock selection and currency.
What we can say is that the fund is not a copy of the index: Its five largest stocks were MPI, Chroma ATE, WinWay Technology, Asia Vital Components, and Fositek, together about 35% of the portfolio.
Investments in these funds are currently stopped because its overseas funds were close to the limit that applies to the whole fund house, set under RBI and SEBI rules. Only the existing SIPs continue.
Since the day it closed, the NAV has fallen from Rs 33.74 to Rs 29.69, a decline of 12%. The fund also carries a very high risk rating on SEBI's riskometer and a short track record, having launched in December 2021.
Up 26% and run by the same manager as above, Kinjal Desai, Nippon India Japan Equity Fund is built very differently.
Its largest holding is SoftBank Group at 3.9% as of 30 September, followed by Tokyo Electron, Sumitomo Electric, SMC, and Tokio Marine, each above 3%, and the top ten make up about 32% of the portfolio.
That spread across robotics, electronics, insurance, and industrial companies is far less concentrated than the Taiwan fund.
The fund has been around since August 2014, so it has a long record.
It has the same closure as the Taiwan fund we discussed above, in force since 21 April 2026, so it also cannot take new money.
The fund is also small, at about Rs 3.6 bn AUM, and a 1% exit load applies within a year.
Part of its rupee return comes from the fall in the rupee, which makes overseas assets worth more in rupees.
Third is Kotak Healthcare Fund.
Up 25.6% against 12.9% for its benchmark, the Nifty Healthcare TRI, a lead of 12.7 percentage points in ten months.
Sun Pharma is its largest stock at about 14% of the portfolio and Divi's Laboratories is second at about 9%, so two companies are over a fifth of the fund.
It launched in December 2023, so it has under three years of history, and it has a 2.39% base expense ratio on the regular plan.
On the fund's factsheet, its one-year return to August was 28.2% against 18.5% for the benchmark. That is the kind of result that can come from a few large positions working, and it can reverse as quickly if pharma stock prices fall.
HDFC Pharma and Healthcare Fund is up 22.9%, and by far the largest of the five domestic funds in the pharma group at about Rs 35 bn.
Its largest stocks on 30 September were Divi's Laboratories (9.4%) and Sun Pharma (8.3%), then Alkem, Cipla, and Apollo Hospitals.
These are the same two names that lead the Kotak fund, which means the two pharma funds in this list are close to the same bet. The fund is managed by Nikhil Mathur and launched in October 2023.
Its record shows how far the ranking depends on the year chosen. The fund returned 8.5% in the 2025-26 financial year, against 28.4% in 2024-25, and 22.9% so far in calendar 2026.
Since launch it has returned 27.8% a year, a figure that comes mainly from a strong run for the pharma sector.
The expense ratio is 2.11% and the exit load is 1% within a year.
Last is BOI's Small Cap fund.
It returned 21.3% while the Nifty Smallcap 250 TRI returned 1.0%, a lead of 20 percentage points.
Its biggest stocks on 30 September were Hero Motors, Sky Gold and Diamonds, City Union Bank, Sterlite Technologies, and Raymond, none above 3%, and the top five are about 13% of the portfolio.
It launched in December 2018 and manages about Rs 36.7 bn under Alok Singh and Nav Bhardwaj. Its expense ratio is 2.17% and it has no exit load.
Its longer record is also strong: 15% over one year, 16.9% over three years and 16.7% over five years, with 24% a year since launch.
A caution applies to the year-to-date number. Small cap funds had a strong 2026 as a category, with 26 of 33 positive, and 24 of 33 beat the index, so a high return here says as much about the segment as about this manager.
A year-to-date table is a snapshot of ten months. It ranks funds on one number, and it favours the funds that owned whatever worked this year. But three things are worth adding:
The next five funds by 2026 return are listed below.
| # | Fund | Category | 2026 return |
|---|---|---|---|
| 6 | WOC Pharma and Healthcare Fund | Pharma and healthcare | 21.10% |
| 7 | TRUSTMF Small Cap Fund | Small cap | 20.70% |
| 8 | SBI Healthcare Opportunities Fund (IDCW option) | Pharma and healthcare | 20.30% |
| 9 | Samco Small Cap Fund | Small cap | 19.60% |
| 10 | Bajaj Finserv Healthcare Fund | Pharma and healthcare | 19.60% |
Overall, whatever the year-end ranking shows, the funds at the top of a one-year table are rarely the ones that stay there.
Fund details should be checked on the fund house's current factsheet before investing.
Happy investing.
Warm regards,
Quantum Information Services Private Limited (Research Analyst)
Disclaimer: This write up is for information purpose and does not constitute any kind of investment advice or a recommendation to Buy / Hold / Sell a fund. Returns mentioned herein are in no way a guarantee or promise of future returns. As an investor, you need to pick the right fund to meet your financial goals. If you are not sure about your risk appetite, do consult your investment consultant/advisor. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully. Registration granted by SEBI, enlistment as RA and IA with Exchange and certification from NISM no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Enter your email to continue reading on Equitymaster.
Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster covering exciting investing ideas and opportunities in India.
Before you continue reading, please go to your inbox and look for confirmation email from us.
Watch out for the subject line 'Verify Your Email for Equitymaster – Your OTP Inside'
If you don't find it in your inbox, please check your spam/junk folder.
Equitymaster requests your view! Post a comment on "5 Best Equity Funds Based on Returns in 2026". Click here!
1 Responses to "5 Best Equity Funds Based on Returns in 2026"
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Quantum Information Services Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Registered Name:
Quantum Information Services Private Limited
Registered Office Address:
103, Regent Chambers, Nariman Point, Mumbai 400021
CIN:
U65990MH1989PTC054667
Website:
Compliance Officer & Grievance Officer:
Ms. Sonal Ramachandran
| Telephone No.: +91-22-61434003 | Email: compliance@equitymaster.comSEBI Registered Research Analyst Details:
SEBI Registration No.: INH000021128 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 6769
Principal Officer: Tanushree Banerjee | Telephone No.:+91-22-61434055 | Email: po.ra@equitymaster.com
SEBI Registered Investment Adviser Details:
SEBI Registration No.: INA000000680 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 1488
Principal Officer: Vivek Chaurasia | Telephone No.:+91-22-61434055 | Email: po.ria@equitymaster.com
SEBI Office Details:
SEBI Bhavan BKC
Address: Plot No.C4-A, 'G' Block Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra
Telephone No.: +91-22-26449000 / 40459000 | Fax: +91-22-26449019-22 / 40459019-22 | Email: sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575
SCORES: https://www.scores.gov.in/ | SMARTODR: https://smartodr.in/login
Association of Mutual Funds of India (AMFI) Registered Details:
AMFI Registered Mutual Fund Distributor
AMFI Registration Number : ARN - 1022
Date of Initial Registration : 28 / JAN / 2008
Current Validity of ARN upto : 28 / JAN / 2028
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.
Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.
The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here

nagarjuna babu
Nov 4, 2026Good analysis